White R P
Department of Pharmacology, University of Tennessee College of Medicine, Memphis.
Neurosurg Clin N Am. 1990 Apr;1(2):401-15.
One hypothesis of cerebral vasospasm contends that the slow onset and eventual disappearance of the spasm of subarachnoid hemorrhage is caused by the finite production of spasmogens. These are generated and accumulate in the basal cisterns as the result of chemical reactions between blood elements, arterial wall, leptomeninges, and brain. The spasmogens may spread in the general direction of bulk CSF flow to affect arteries more distally. Pharmacodynamic studies performed on isolated cerebral arteries show that a vast array of naturally occurring substances are vasoactive. Among these, derivatives of arachidonate (eicosanoids) are strong candidates as spasmogens because they produce strong, prolonged contractions in human arteries and because the CSF levels of some eicosanoids are preferentially elevated in subarachnoid hemorrhage patients who experience severe spasm. The spasm may be largely refractory to treatment because the intravasation of blood elements and the coagulum serve as barriers to therapeutic agents and because cerebral arteries are devoid of vasa vasorum; however, in animal models of chronic subarachnoid hemorrhage, calcium antagonists given intrathecally will reverse the spasm. Other therapeutic strategems are being tried experimentally and clinically, including compounds like prostacyclin that relax cerebral arteries and inhibit platelets. In vitro studies indicate further that some plasma proteins (e.g., haptoglobin, antithrombin III) and several products of endothelial synthesis (PGI2, EDRF) may naturally provide protection against the genesis of vasospasm. The in vitro responses to bloody CSF are capricious but are not due to many pharmacologically defined substances, including hemoglobin. Hemoglobin and its derivatives, however, may be critical to the enhanced lipid peroxidation and free-radical production that occur in subarachnoid hemorrhage.
一种关于脑血管痉挛的假说认为,蛛网膜下腔出血后痉挛的缓慢发作及最终消失是由血管痉挛原的有限产生所引起的。这些血管痉挛原是血液成分、动脉壁、软脑膜和脑之间发生化学反应的结果,在脑基底池产生并积聚。血管痉挛原可能会大致顺着脑脊液的总体流动方向扩散,从而影响更远端的动脉。对离体脑动脉进行的药效学研究表明,大量天然存在的物质具有血管活性。其中,花生四烯酸的衍生物(类二十烷酸)很可能是血管痉挛原,因为它们能使人体动脉产生强烈且持久的收缩,还因为在经历严重痉挛的蛛网膜下腔出血患者中,某些类二十烷酸的脑脊液水平会优先升高。这种痉挛可能在很大程度上难以治疗,因为血液成分的侵入和血凝块会成为治疗药物的屏障,还因为脑动脉没有血管滋养管;然而,在慢性蛛网膜下腔出血的动物模型中,鞘内注射钙拮抗剂可逆转痉挛。其他治疗策略正在进行实验和临床尝试,包括诸如前列环素这类能舒张脑动脉并抑制血小板的化合物。体外研究进一步表明,一些血浆蛋白(如触珠蛋白、抗凝血酶III)以及内皮合成的几种产物(前列环素、内皮舒张因子)可能天然地提供了针对血管痉挛发生的保护作用。对血性脑脊液的体外反应变幻莫测,但并非由包括血红蛋白在内的许多药理学明确的物质所致。然而,血红蛋白及其衍生物可能对蛛网膜下腔出血中发生的脂质过氧化增强和自由基产生至关重要。